First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population [0.03%]
一种一线细胞周期素依赖性激酶4和6抑制剂与芳香化酶抑制剂联合用于HR+/HER2-转移性乳腺癌：在美国符合条件的 Medicare 人群中进行的真实世界成本效益评估
Lucille Sun,David L Veenstra,Adam Brufsky et al.
Lucille Sun et al.
Background: In hormone receptor-positive, human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC), cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) in combination with an aromatase inhibit...
Ustekinumab infusion to subcutaneous transition: Coordinating care and identifying potential gaps [0.03%]
乌司奴单抗从输液转为皮下注射：协调治疗和识别潜在缺口
Chelsea P Renfro,Jessica Fann,Josh DeClercq et al.
Chelsea P Renfro et al.
Background: Ustekinumab, approved for the treatment of moderate to severe Crohn disease (CD) and ulcerative colitis (UC), requires a clinic-administered intravenous (IV) induction infusion (loading dose) followed by trans...
The effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa [0.03%]
关于视网膜母细胞病毒载体ISTEPARVOVEC治疗晚期色素性视网膜炎有效性和价值的系统评价和 meta 分析
Belen Herce-Hagiwara,Avery McKenna,Anil N Makam et al.
Belen Herce-Hagiwara et al.
Will the emerging private-label market access channel help or hinder biosimilar market access? [0.03%]
新兴的自有品牌市场准入渠道将会促进还是阻碍生物类似药的市场准入？
Stanton R Mehr
Stanton R Mehr
Until April 2024, adalimumab biosimilar uptake remained stagnant at 2% to 3%; the 3 largest pharmacy benefit managers (PBMs), which control 80% of prescriptions dispensed in the United States, maintained the reference product on formulary. ...
Real-world use of biologic and targeted synthetic disease-modifying antirheumatic drugs in US patients with psoriatic arthritis: Persistence, patient characteristics associated with discontinuation, and dosing patterns [0.03%]
美国银屑病关节炎患者的生物制剂和目标改善病情的抗风湿药的实际应用：持续性，停药相关的患者特征以及给药模式
Joseph F Merola,Sarah Welby,Helena Roque et al.
Joseph F Merola et al.
Background: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory arthropathy presenting with multiple manifestations, including peripheral arthritis, enthesitis, and skin psoriasis (PSO). Immunosuppressive...
Caring for communities: A 4-year pharmacy partnership focused on diabetes and cardiovascular health [0.03%]
关爱社区：一个为期四年的以糖尿病和心血管健康为重点的药房合作项目
Wesley Nuffer,Angela Thompson,Kelly Stenhoff et al.
Wesley Nuffer et al.
Current community pharmacy practice faces several substantial pressures affecting the business model. Transitioning to a more patient-centered focus and providing additional direct patient care services that will eventually be billed for an...
Real-time continuous glucose monitoring vs self-monitoring of blood glucose in distinct multi-ethnic cohorts of patients living with insulin-treated type 2 diabetes in the United States: A cost-utility analysis from a Medicare perspective [0.03%]
美国以医疗保险角度看待实时连续葡萄糖监测与自我监测血糖在美国采用胰岛素治疗的多族裔2型糖尿病患者中的成本效益分析
Hamza Alshannaq,Jessica Matuoka,Richard F Pollock et al.
Hamza Alshannaq et al.
Background: For individuals living with type 2 diabetes (T2D) requiring insulin therapy, the use of real-time continuous glucose monitoring (rt-CGM) yields significant clinical benefits relative to self-monitoring of bloo...
Identifying and characterizing commercially insured patients with HFpEF with high vs low health care resource utilization [0.03%]
高医疗资源利用率与低医疗资源利用率的商业保险心力衰竭患者的特征分析
Jacob Earl,Laura A Hart,Ryan N Hansen
Jacob Earl
Background: Heart failure with preserved ejection fraction (HFpEF) represents half of all HF diagnoses and is a growing public health concern. Despite therapeutic advancements, HFpEF contributes to substantial health care...
Group-based trajectory modeling to assess adherence to chronic urate-lowering therapies among commercially insured US adults with gout [0.03%]
基于群体的轨迹模型评估美国商业保险成人痛风患者长期尿酸降低治疗依从性的方法
John G Rizk,Danya M Qato,Clifton O Bingham et al.
John G Rizk et al.
Background: The benefits of urate-lowering therapies (ULTs) for the long-term management of gout are well established. However, suboptimal adherence remains a significant challenge, resulting in increased gout flares and ...
Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals: An analysis using the Premier Healthcare Database [0.03%]
美国医院接受Teclistamab治疗多发性骨髓瘤的初治患者真实世界特征和剂量递增过程：基于Premier卫生保健数据库的分析研究
Carlyn Rose Tan,Eric Chinaeke,Nina Kim et al.
Carlyn Rose Tan et al.
Background: Teclistamab is the first-in-class B cell maturation × cluster of differentiation 3 T cell bispecific antibody approved in the United States for relapsed or refractory multiple myeloma (MM). During the first y...